U.S. Department of Health and Human Services
Staff Search  
 

 Staff Contacts

 

Division of Diabetes, Endocrinology and Metabolic Diseases

Division of Kidney, Urologic and Hematologic Diseases

Division of Digestive Diseases and Nutrition

U34 Frequently Asked Questions

​Some of the most common questions about the U34 are answered below.

Introduction

What are the U34 Multi-Center Clinical Study Implementation Planning Grant and the U01 Multi-Center Clinical Study Cooperative Agreement Grant?

NIDDK will support investigator-initiated, multi-center clinical studies exclusively through a two part grant process: (1) an implementation planning (U34) grant followed by (2) a cooperative agreement (U01) to conduct the study. Investigators interested in conducting an NIDDK-funded multi-center clinical study must receive a U34 Multi-Center Clinical Study Implementation Planning Grant before a U01 Multi-Center Clinical Study Cooperative Agreement grant will be awarded, except in cases where an exemption is granted.
 
This policy applies to all clinical studies, interventional trials as well as observational studies, conducted at three or more sites. NIDDK will not accept applications for multi-center clinical studies that are submitted as R01s, with the exception of ancillary studies to existing cooperative agreements, which can be submitted as R01s to PAR-12-265, or applications submitted to other future FOAs.
 
This policy does not apply to pilot studies. Investigators who are interested in obtaining support for pilot studies may use the R21 mechanism, through the appropriate program announcement (see question #5, below).
 
Please note: the U34 implementation planning grant application must include the proposed study protocol.​


Why is NIDDK requiring a U34 Multi-Center Clinical Study Implementation Planning Grant before they will fund a U01 Multi-Center Clinical Study Cooperative Agreement?

​Clinical studies require extensive administrative planning (e.g., protocol finalization, manual of operations development, case report form design, data management and study oversight, etc.) before participant recruitment may begin. These activities require significant resources and personnel; thus, the administrative planning process typically begins after the study has been peer-reviewed and funded. The U34 Multi-Center Clinical Study Implementation Planning Grant mechanism will provide sufficient time and funds to complete detailed clinical study activities/documents necessary to comply with NIDDK standards and regulatory requirements. The product of an awarded U34 Multi-Center Clinical Study Implementation Planning Grant will be an application (U01 Multi-Center Clinical Study Cooperative Agreement) to conduct the clinical study.
 
After successfully completing the administrative implementation activities of the U34 Multi-Center Clinical Study Implementation Planning Grant, investigators can apply for a U01 Multi-Center Clinical Study Cooperative Agreement grant and request up to 5 years to conduct the clinical study.


Is the U34 Multi-Center Clinical Study Implementation Planning Grant limited to multi-center clinical trials?

​No. The U34 Multi-Center Clinical Study Implementation Planning Grant mechanism is designed to support the planning activities of all types of multi-center clinical studies including epidemiologic studies, observational studies, and interventional clinical trials. A multi-center study is one which is conducted at three or more sites.


What administrative study activities are the U34 Multi-Center Clinical Study Implementation Planning Grant designed to support?

​Study-related activities conducted during the U34 Multi-Center Clinical Study Implementation Planning Grant will depend on the type of clinical study (e.g., epidemiologic study, drug trial, behavior intervention). The U34 planning grant may support activities such as, but not limited to, the development/completion of the following items:

  • Final study protocol. Please note that a proposed protocol must be included in the U34 application, as an appendix. The U34 period may be used to modify and/or finalize the protocol, if necessary, based on comments received during the review process, logistical issues or new scientific progress during the U34 period
  • Informed consent form(s) and, if applicable, assent form(s)
  • Investigator’s brochure or equivalent
  • Manual of operations including details, validation, and quality control for any non-standard clinical or laboratory/mechanistic testing which will be performed
  • Data monitoring and management plan
  • A plan for the acquisition and administration of study agent(s) or device(s)
  • Required Office of Human Research Protections assurances if not already in place
  • Complete set of suitable documents for submission to the appropriate regulatory authorities
  • Safety oversight plan
  • Detailed budget for conduct and completion of the clinical trial including funding for preparation of a final study report
  • Identification of clinical study site(s)
  • Training materials and training/certification plans for study staff
  • Initial IRB approval
  • Applicable regulatory elements of the Food and Drug Administration if an IND/IDE is needed for implementation of the research plan
  • Agreements with industry, as needed, to provide drugs, devices, or other resources
  • In the event of an award, the NIDDK and the Principal Investigator will agree on a list of milestones to be completed during the U34 Multi-Center Clinical Study Implementation Planning Grant project period


Can the U34 Multi-Center Clinical Study Implementation Planning Grant be used to collect preliminary data or to conduct a pilot study in preparation for a multi-site clinical study?

​No, the U34 Multi-Center Clinical Study Implementation Planning Grant is not designed for the collection of preliminary data, for the conduct of pilot studies to support the rationale for a clinical study, or for the design of the study. The proposed study design and protocol will be key elements in the peer-review of all U34 Multi-Center Clinical Study Implementation Planning Grant applications. 
 
NIDDK supports R21 Program Announcements to support the collection of preliminary data and for conduct of pilot studies. See:


Can the U34 Multi-Center Clinical Study Implementation Planning Grant be used to support a group of investigators who wish to meet and plan a multi-center study?

​No. The U34 Multi-Center Clinical Study Implementation Planning Grant is not designed for this purpose. The U34 application must include details of the proposed study design and a proposed protocol, which will be critically evaluated during the peer-review process.


Logistics

How many years of support and what level of funding will the U34 Multi-Center Clinical Study Implementation Planning Grant mechanism provide?

​Because the nature and scope of the proposed research will vary from application to application, it is anticipated that the size and duration of each award will also vary. The total project period for an application submitted in response to the U34 Multi-Center Clinical Study Implementation Planning Grant funding opportunity may not exceed two years. Applicants may request up to $250,000 in direct costs per year (excluding consortium Facilities and Administrative [F&A] costs). The funds requested are expected to vary based on the number of clinical sites involved in the study and the complexity of the study.


Do all U34 Multi-Center Clinical Study Implementation Planning Grant applications have to request two years of funding to complete the administrative planning process?

​No. U34 Multi-Center Clinical Study Implementation Planning Grant applications are not required to request two years of funding. Applicants may request less than 2 years of funding if, in the applicant’s judgment, the planning process will require less than 2 years of grant support.


Will renewal applications be accepted for U34 Multi-Center Clinical Study Implementation Planning Grants?

​No. Renewal applications will not be accepted for U34 Multi-Center Clinical Study Implementation Planning Grants. The U34 grant mechanism will provide up to a maximum of 2 years of funding to support the planning activities required of new projects.


If a U34 Multi-Center Clinical Study Implementation Planning Grant is awarded, what role will NIDDK have in the implementation of the grant?

​The U34 Multi-Center Clinical Study Implementation Planning Grant will use a cooperative agreement award mechanism. In the cooperative agreement mechanism, the Project Director/Principal Investigator (PD/PI) retains the primary responsibility and dominant role for planning the proposed project, with NIH staff being substantially involved as a partner with the Principal Investigator, as described under Section VI. 2. Administrative Requirements, Cooperative Agreement Terms and Conditions of Award in PAR-13-268.


Application

What should I do if I want to submit a U34 Multi-Center Clinical Study Implementation Planning Grant?

​Applicants are strongly encouraged to contact the appropriate NIDDK Program Director to discuss their proposed application for a U34 Multi-Center Clinical Study Implementation Planning Grant. Program staff will help the investigator understand whether the proposed full clinical study addresses a high priority research area and meets programmatic needs including balance across research areas, whether it is appropriate to conduct using this mechanism, and whether funds might be available for the subsequent, full clinical study. See the NIDDK Research Areas to identify the correct program director for your application. If you are not sure of the appropriate program director, you can contact one of the program directors designated as contacts for information in the PAR (PAR-13-268) and you will be directed to the appropriate individual.


How far in advance of the U34 Multi-Center Clinical Study Implementation Planning Grant application receipt date should I contact NIDDK?

​You should contact the appropriate Program Director at least 6 weeks before the desired receipt date. However, to take the best advantage of the prior consultation process, contact should be initiated as soon as possible. Since this is a cooperative agreement, NIDDK will ultimately have substantive scientific involvement with the proposed project. NIDDK will need sufficient time to thoroughly consider the proposed study. It is the Institute’s experience that applications for multi-center clinical studies may be scientifically meritorious but often need further work before they are ready for submission. Allotting more than 6 weeks for the consultation process will allow time for revisions, should they need to be made.


What information should be included in a letter requesting consultation about applying for a U34 Multi-Center Clinical Study Implementation Planning Grant?

​The details included in your letter may vary depending on the type of study planned (e.g., epidemiology study, drug trial, behavior intervention). Generally, the letter should include all of the following items: 

  • Date of Proposed Submission
  • Study title
  • Study PI (including biosketch)
  • Primary institution
  • Specific Aims
  • Significance
  • Summary of study protocol, including flow diagram depicting study
  • Summary of safety/risk issues
  • Proposed start date, duration, and timeline of the clinical trial
  • Estimated sample size including brief power calculation
  • General statistical assumptions for the proposed study design and analysis
  • Potential collaborating sites, including the demographics and availability of the study population at those sites. Include identification and a brief description of the Data Coordinating Center
  • Discussion of product/intervention to be evaluated and how it will be obtained, if applicable, including industry partner(s) and regulatory issues that have/need to be resolved
  • Total cost for the U34 phase
  • Total cost estimate of the clinical study, not the planning grant, by year
  • Milestones to be accomplished during the U34


Who should I contact for prior consultation?

​You should contact the appropriate program director for the subject matter of the application. See the NIDDK Research Areas to identify the correct program director for your application.  If you are not sure of the appropriate program director, you can contact one of the program directors designated as contacts for information in the PAR and you will be directed to the appropriate individual PAR-13-268.


Is a U34 Multi-Center Clinical Study Implementation Planning Grant always required by NIDDK before a multi-center clinical study can be funded?

​A U34 Multi-Center Clinical Study Implementation Planning Grant is required by NIDDK before a multi-center clinical study is funded by a U01 mechanism, except in cases where an exemption from this requirement has been provided by NIDDK.


How may requests for exemption from a U34 Multi-Center Clinical Study Implementation Planning Grant be submitted?

​Investigators who believe that they have completed all the steps normally conducted during the U34 Multi-Center Clinical Study Implementation Planning Grant phase of the two-part grant process (U34/U01) may request an exemption from the U34 planning grant requirement. Investigators seeking such an exemption should contact the appropriate program director for the subject matter of the application.  See the NIDDK Research Areas to identify the correct program director for your application. If you are not sure of the appropriate program director, you can contact one of the program directors designated as contacts for information in the PAR and you will be directed to the appropriate individual. PAR-13-268


If a U34 Multi-Center Clinical Study Implementation Planning Grant is awarded, will NIDDK guarantee that a subsequent U01 Multi-Center Clinical Study Cooperative Agreement will also be awarded?

​No. Prospective applicants should note that obtaining a U34 Multi-Center Clinical Study Implementation Planning Grant award does not guarantee or imply funding for a subsequent U01 Multi-Center Clinical Study Cooperative Agreement application. If the planning phase is not successful, the NIDDK may decide not to allow a U01 Multi-Center Clinical Study Cooperative Agreement application. All U01 Multi-Center Clinical Study Cooperative Agreement applications will be peer-reviewed, and NIDDK will consider the results of the peer-review process when deciding whether to support the U01 Multi-Center Clinical Study Cooperative Agreement.


Peer Review

How will a U34 Multi-Center Clinical Study Implementation Planning Grant application be peer-reviewed?

​U34 Multi-Center Clinical Study Implementation Planning Grant applications will be peer reviewed by special emphasis panels set up by the NIDDK Review Branch. Specific review criteria used to evaluate U34 applications may be found in the PAR.


When are the receipt dates for U34 Multi-Center Clinical Study Implementation Planning Grant applications?

  • April 15, 2014
  • February 19, 2015
  • June 17, 2015
  • April 18, 2016
  • February 14, 2017


Since the U34 grant only supports administrative activities to prepare to conduct the clinical study, why does the peer-review of the U34 include a review of the rationale and design of the proposed clinical study?

​NIDDK will only support the planning phase of a multi-center clinical study if the proposed clinical study is worthy of support. Therefore, the review of the U34 Multi-Center Clinical Study Implementation Planning Grant will include the rationale and design of the proposed clinical study, as well as a proposed protocol. If the clinical study is not significant, innovative and/or likely to answer the proposed research question, NIDDK may decide that the proposed clinical study does not meet the criteria for support of the planning phase of the study.


Since the U34 grant will only support administrative planning (e.g., protocol finalization, manual of operations development) required before subject recruitment can occur, how will peer-review evaluate the significance of a U34 grant application?

Reviewers will be asked to evaluate the innovation of the proposed study based on the rationale and design of the multi-center clinical study to be conducted after the planning phase of the U34. Reviewers may be asked to address questions such as, but not limited to, the following:

  • Is the multi-center clinical study to be conducted after the U34 planning phase original and innovative?
  • Does the project challenge existing paradigms or clinical practice?
  • Will the study address an innovative hypothesis or critical barrier to progress in the field?
  • Does the project develop or employ novel concepts, approaches, methodologies, tools, or technologies for this area?


How will the approach of the U34 grant application be evaluated? Will the peer-reviewers evaluate the approach of the multi-center clinical study or the approach of the U34 planning activities proposed in the application?

​Both the approach of the U34 planning activities and of the proposed multi-center clinical study will be evaluated during peer-review of the U34 Multi-Center Clinical Study Implementation Planning Grant. Peer-reviewers will be asked to evaluate the following questions:

  • Will the study concept and design, methods, and analyses, including preliminary statistical analyses, successfully accomplish the aim(s) of the proposed clinical study?
  • Are the conceptual or clinical framework, design, methods, and analyses adequately developed, well integrated, well-reasoned, and appropriate to the aims of the project?
  • Are the activities proposed for the planning period adequate? Will the activities proposed be sufficient to allow for timely and successful study implementation?
  • Does the applicant acknowledge potential problem areas and consider alternative tactics?
  • Will the proposed planning activities address all major barriers that may confront the U01 clinical study, if accepted?
  • For applications designating multiple PDs/PIs, does the Leadership Plan ensure that there will be sufficient coordination and communication among the PDs/PIs?
  • Are the administrative plans for the management of the research project appropriate, including plans for resolving conflicts?


Revised U34 Multi-Center Clinical Study Implementation Planning Grant Applications

Since the U34 grant only supports administrative activities to prepare to conduct the clinical study, why does the peer-review of the U34 include a review of the rationale and design of the proposed clinical study?

​NIDDK will only support the planning phase of a multi-center clinical study if the proposed clinical study is worthy of support. Therefore, the review of the U34 Multi-Center Clinical Study Implementation Planning Grant will include the rationale and design of the proposed clinical study, as well as a proposed protocol. If the clinical study is not significant, innovative and/or likely to answer the proposed research question, NIDDK may decide that the proposed clinical study does not meet the criteria for support of the planning phase of the study.


If a U34 Multi-Center Clinical Study Implementation Planning Grant application is not funded upon initial submission, can the application be revised and resubmitted?

​Yes. However, investigators are strongly encouraged to discuss the resubmission with their Program Director. NIDDK will consider the comments of the peer-reviewers in discussing a resubmission application with the investigator.


What are the receipt dates for revised U34 Multi-Center Clinical Study Implementation Planning Grant applications?

  • ​April 15, 2014
  • February 19, 2015
  • June 17, 2015
  • April 18, 2016
  • February 14, 2017


Since the U34 grant will only support administrative planning (e.g., protocol finalization, manual of operations development) required before subject recruitment can occur, how will peer-review evaluate the significance of a U34 grant application?

Reviewers will be asked to evaluate the innovation of the proposed study based on the rationale and design of the multi-center clinical study to be conducted after the planning phase of the U34. Reviewers may be asked to address questions such as, but not limited to, the following:

  • Is the multi-center clinical study to be conducted after the U34 planning phase original and innovative?
  • Does the project challenge existing paradigms or clinical practice?
  • Will the study address an innovative hypothesis or critical barrier to progress in the field?
  • Does the project develop or employ novel concepts, approaches, methodologies, tools, or technologies for this area?